Carpe Diem

Tag: FunStock

Kodiak Sciences KOD FunStock dashboard tracking institutional ownership, short interest, financials and Phase 3 biotech results.

Kodiak Sciences (KOD): Why the FunStock Gauges Keep Running After You Buy

Kodiak Sciences was around $26 when we published our cautiously bullish analysis after Baker Bros. made a major investment. Nine months later, KOD closed at $89.92 after successful Phase 3 results. But the bigger lesson may be what the FunStock gauges revealed along the way.

Read entire article

Tags: Baker Bros Advisors, Baker Brothers, biotech investing, biotech stocks, Carpe Diem, FDA approval, FunStock, FunStock Method, growth stocks, hedge funds, insider investing, institutional ownership, investment research, KOD, KOD stock, Kodiak Sciences, Kodiak Sciences stock, KSI-501, Phase 3 clinical trials, retinal disease, short interest, short squeeze, speculative investing, tabirafusp-ted, wet AMD, Zenkuda
Editorial illustration showing Wall Street analysts shifting sentiment on PayPal stock from bullish at its 2021 peak to bearish after its decline, highlighting market psychology and analyst herd behavior.

📉 When Everyone Loved PayPal… That Was the Problem

In 2021, over 90% of analysts rated PayPal a Buy as the stock traded near $300 — with zero Sell ratings. Today, at $55, sentiment has flipped bearish. Same company, different crowd. A classic contrarian lesson.

Read entire article

Tags: Analyst Ratings, buy or sell PYPL, Buy the Dip?, contrarian investing, FUNanc1al Edge, FUNanc1al Humor, FUNanc1al Investing, FunStock, Herd Mentality, Institutional Behavior, Market Psychology, Market Timing, PayPal, PYPL, Wall Street Sentiment